| Literature DB >> 26639405 |
Nicolina Cristina Sorrentino1, Veronica Maffia1, Sandra Strollo1, Vincenzo Cacace1, Noemi Romagnoli2, Anna Manfredi1, Domenico Ventrella2, Francesco Dondi2, Francesca Barone2, Massimo Giunti2, Anne-Renee Graham3, Yan Huang3, Susan L Kalled3, Alberto Auricchio4, Maria Laura Bacci2, Enrico Maria Surace5, Alessandro Fraldi6.
Abstract
Cerebrospinal fluid administration of recombinant adeno-associated viral (rAAV) vectors has been demonstrated to be effective in delivering therapeutic genes to the central nervous system (CNS) in different disease animal models. However, a quantitative and qualitative analysis of transduction patterns of the most promising rAAV serotypes for brain targeting in large animal models is missing. Here, we characterize distribution, transduction efficiency, and cellular targeting of rAAV serotypes 1, 2, 5, 7, 9, rh.10, rh.39, and rh.43 delivered into the cisterna magna of wild-type pigs. rAAV9 showed the highest transduction efficiency and the widest distribution capability among the vectors tested. Moreover, rAAV9 robustly transduced both glia and neurons, including the motor neurons of the spinal cord. Relevant cell transduction specificity of the glia was observed after rAAV1 and rAAV7 delivery. rAAV7 also displayed a specific tropism to Purkinje cells. Evaluation of biochemical and hematological markers suggested that all rAAV serotypes tested were well tolerated. This study provides a comprehensive CNS transduction map in a useful preclinical large animal model enabling the selection of potentially clinically transferable rAAV serotypes based on disease specificity. Therefore, our data are instrumental for the clinical evaluation of these rAAV vectors in human neurodegenerative diseases.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26639405 PMCID: PMC4817820 DOI: 10.1038/mt.2015.212
Source DB: PubMed Journal: Mol Ther ISSN: 1525-0016 Impact factor: 11.454